Development of Human Carbonic Anhydrase II Heterobifunctional Degraders
Journal of Medicinal Chemistry · 23.02.2023 · 66 (4) · 2789-2803
DOI: 10.1021/acs.jmedchem.2c01843 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.02.2023. Verfasst von Conor B O'Herin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, University of California, La Jolla, California 92093, United States. Hauptthemen laut MEDLINE: Carbonic Anhydrase II, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Human carbonic anhydrase II (hCAII) is a metalloenzyme essential to critical physiological processes in the body. hCA inhibitors are used clinically for the treatment of indications ranging from glaucoma to epilepsy. Targeted protein degraders have emerged as a promising means of inducing the degradation of disease-implicated proteins by using the endogenous quality control mechanisms of a cell. Here, a series of heterobifunctional degrader candidates targeting hCAII were developed from a simple aryl sulfonamide fragment. Degrader candidates were functionalized to produce either cereblon E3 ubiquitin ligase (CRBN) recruiting proteolysis targeting chimeras (PROTACs) or adamantyl-based hydrophobic tags (HyTs). Screens in HEK293 cells identified two PROTAC small-molecule degraders of hCA. Optimization of linker length and composition yielded a degrader with sub-nanomolar potency and sustained depletion of hCAII over prolonged treatments. Mechanistic studies suggest that this optimized degrader depletes hCAII through the same mechanism as previously reported CRBN-recruiting heterobifunctional degraders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, University of California, La Jolla, California 92093, United States.
ORCID-Profile: Michael D Burkart, Seth M Cohen
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NCI NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Zitieren
APA
O'Herin, C. B., Moriuchi, Y. W., Bemis, T. A., Kohlbrand, A. J., Burkart, M. D., & Cohen, S. M. (2023). Development of Human Carbonic Anhydrase II Heterobifunctional Degraders. Journal of Medicinal Chemistry, 66(4), 2789-2803. https://doi.org/10.1021/acs.jmedchem.2c01843
Vancouver
O'Herin CB, Moriuchi YW, Bemis TA, Kohlbrand AJ, Burkart MD, Cohen SM. Development of Human Carbonic Anhydrase II Heterobifunctional Degraders. Journal of Medicinal Chemistry. 2023;66(4):2789-2803. doi:10.1021/acs.jmedchem.2c01843
BibTeX
@article{OHerin2023,
author = {O'Herin, Conor B and Moriuchi, Yuta W and Bemis, Troy A and Kohlbrand, Alysia J and Burkart, Michael D and Cohen, Seth M},
title = {Development of Human Carbonic Anhydrase II Heterobifunctional Degraders},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {4},
pages = {2789--2803},
doi = {10.1021/acs.jmedchem.2c01843}
}
EUVIMED